R&D

What is the future of healing?

What is the future of healing?

Written by on July 23, 2014 in Research & Development with 0 Comments

What is the future of the healthcare industry? What will the healing of tomorrow look like? CNN’s Top 10 may have the answer! CNN have taken a closer look at the innovations of today that could lead to the cures of tomorrow. Below is a brief run down of CNN’s top 10. Find out more […]

Continue Reading

Clinical Trials: Cooperation and Big Data Sharing is the Way Forward

Clinical Trials: Cooperation and Big Data Sharing is the Way Forward

Big Pharma companies are hiring Big Data analytics firms to protect privacy of shared data Important initiatives are emerging for big pharma companies to render their trials results accessible to other companies and to researchers. The spread of this tendency would make drug development more efficient and save the industry billions. Indeed, if researchers could […]

Continue Reading

Drug Discovery

The future of pharma innovation: Genomic medicine

The future of pharma innovation: Genomic medicine

Written by on July 25, 2014 in Biosimilars, Drug Discovery with 0 Comments

The future of drug development is undoubtedly tied to personalizing medicine. Understanding a person’s genetic makeup in order to not only detect but treat diseases is at the forefront of medicine nowadays. The Mexican pharma industry has joined this trend as several companies are joining efforts with research institutions to look at the diversity of […]

Continue Reading

Download the Interview: Boosting the Innovation Machine in Pharma R&D

Download the Interview: Boosting the Innovation Machine in Pharma R&D

An interview with François-Henri Boissel, CEO of Novadiscovery, on Pharma R&D biggest challenges and the need for a new innovation paradigm. Download a copy here In this interview, we asked François-Henri Boissel, CEO of Novadiscovery, for his view on the traditional drug R&D process, and how it could be modified to better predict real world performance and adverse events. […]

Continue Reading

Clinical Trials

Clinical Trial Management System Market, Trends and Forecasts

Clinical Trial Management System Market, Trends and Forecasts

Written by on July 24, 2014 in Clinical Trials with 0 Comments

A new report has stated that the global Clinical Trial Management System (CTMS) market “is expected to grow at a CAGR (compound annual growth rate) of 14% from 2014 to 2019, to reach an estimated value of USD 1,848.5 million in 2019″, compared with USD 844.0 million in 2013. CTMS is a software system which […]

Continue Reading

Delay for Clinical Trial Data Publication Policy Adoption

Delay for Clinical Trial Data Publication Policy Adoption

Written by on July 17, 2014 in Clinical Trials with 0 Comments

The EU Clinical Trials Regulation has been drafted over and over again and now it would appear that another facet of it will be rethought. Proposals which would have allowed secondary researchers to download, save and print clinical trial data will now not be formally adopted until October. This is because the European Medicines Agency […]

Continue Reading

Manufacturing

Business-development, manufacturing and marketing of cell-based medicinal products

Business-development, manufacturing and marketing of cell-based medicinal products

  Kunihiko Suzuki, President and Chief Executive Officer, Medinet Co Ltd joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on ‘Pursuing cell-based medicinal product business-development, manufacturing and marketing cell-based medicinal products.’ Download this presentation now to find out: New Regulatory Framework for Regenerative Medicine in JAPAN Development of […]

Continue Reading

Download: Advanced 2nd generation media development and application

Download: Advanced 2nd generation media development and application

Written by on July 28, 2014 in Cell Culture, Manufacturing with 0 Comments

Dr. Torsten W. Schulz, Executive Director, Head Upstream Manufacturing at Boehringer Ingelheim Pharma joined us at the 4th Annual Cell Culture World Congress with a talk entitled ‘Boosting the output: Advanced 2nd generation media development and application for the biopharmaceutical industry.’ The talk explored experimental workflow followed by two case studies. Torsten kindly made his […]

Continue Reading

Regulation & Compliance

Download: Morality and the Pharma industry

Download: Morality and the Pharma industry

  Pharma is facing ever increasing transparency regulations in Europe. The risk of severe fines and a tarnished reputation means pharma companies need to make sure they are managing risk and adopting ethical business practices. This topic was discussed in detail during a presentation given by Dr Nick Broughton, Managing Director, Pharmaceuticalethics.com at Pharma Compliance Europe 2013. […]

Continue Reading

Download: Effective development and implementation of a compliance programme

Download: Effective development and implementation of a compliance programme

Written by on July 22, 2014 in Featured on app, Regulation and Compliance, Reports with 0 Comments

Kristine Aachmann Bethe, Corporate Counsel, Business Ethics Compliance Office, Novo Nordisk A/S gave a presentation at Pharma Compliance 2013 on the effective development and implementation of a compliance programme. Her presentation began by highlighting why compliance is so important to Novo Nordisk, explaining that now, as part of big pharma, there are increased demands and expectations to […]

Continue Reading

Pricing & Market Access

AstraZeneca’s Ajay Gautam on Innovative R&D for Emerging Markets

AstraZeneca’s Ajay Gautam on Innovative R&D for Emerging Markets

We were glad to have Ajay Gautam, Executive Director and Head of Emerging Markets R&D at AstraZeneca, present at last year’s BioPharma Mexico. You can now download his slides from the event, where he addressed innovative R&D models for emerging markets under the main heading “How to grow the Mexican pharma industry”. View the presentation […]

Continue Reading

Pharma M&A on Steroids: Pfizer Breakdown

Pharma M&A on Steroids: Pfizer Breakdown

Pharma M&A activity has seen such an uptake in recent weeks and the industry is alive with developments and momentum. Andrew Badrot, a speaker at the Pharma M&A Briefing on 10th June has kindly analysed the role that Pfizer has played in the market in this guest blog. The industry has been on a roller […]

Continue Reading

Engagement & Marketing

Patient opinion leaders: the new KOLs for pharma?

Patient opinion leaders: the new KOLs for pharma?

Written by on July 28, 2014 in Engagement & Communications with 0 Comments

The emergence of ultra-informed patients via social media is changing how medicine is practiced at every level. Such people, otherwise known as patient opinion leaders (POLs), are highly health literate and, via impressive followings on the web and beyond, can be regarded as a new breed of key opinion leader (KOL) influencing both their fellow […]

Continue Reading

Who is pushing the boundaries in pharma engagement?

Who is pushing the boundaries in pharma engagement?

Written by on July 22, 2014 in Engagement & Communications, Featured Videos with 0 Comments

It is one thing to discuss and debate the benefits of evolving Pharma businesses with multichannel engagement strategy, but who is actually doing it? This question was posed to two of our attendees at DigiPharm 2013, Tim Ringrose, CEO, Networks in Health and Ken Phillips, Client Director, eGain. Take a look at the video for […]

Continue Reading

Partnering & Investment

Announcing The Marriage of Big Pharma and Big Data

Announcing The Marriage of Big Pharma and Big Data

Novartis teams up with Google to develop “smart” lens This week a partnership between Goggle and Novartis has been announced, for the development of a “smart” contact lens to help diabetics track their blood sugar levels. This is the first big partnership made public between big pharma and big data to work together to revolutionise […]

Continue Reading

Today and tomorrow’s world – not-for-profits join with industry to develop drugs

Today and tomorrow’s world – not-for-profits join with industry to develop drugs

Written by on July 17, 2014 in Partnering & Investment with 0 Comments

I’ve had several conversations with pharmaceutical industry experts in the last few days. There seems to be increasing interest from sponsors marrying up with research charities. I thought that I would share some examples with you. Cancer Research UK developed Clinical Development Partnerships (CDP) meaning that de-prioritised agents can be given a second chance. The […]

Continue Reading

Other Recent Posts

ISTO Technologies President and CEO on Growing Multi-Purpose Cartilage Tissue

Mitchell Seyedin, President and Chief Executive Officer of ISTO Technologies, presented at the Stem Cells & Regenerative Medicine Congress in 2013. You can now view the video of his presentation, where he addressed growing multi-purpose cartilage tissue. Mitchell has been the President and CEO of ISTO Technologies Inc since September of 2003. He has been […]

Continue Reading

The Protein A Debate: should we still be looking for alternatives?

Interest in researching a cost effective alternative to Protein A has waned in current years. Should we still be on the lookout for other methods of antibody extraction? Protein A is an essential but costly tool in the manufacture of most monoclonal antibodies (MAb). Protein A makes up approximately 30% of the total cost of […]

Continue Reading

Your ticket to Total Biopharma networking… Shhhhh, it’s a secret!

Total Biopharma invites all UK-based life science professionals to our monthly industry meet-ups! Running on the first Tuesday of every month, we are hosting these informal industry networking evenings at an assortment of secret London locations.  They are for all local life science professionals looking to build their networks and meet with like-minded people over […]

Continue Reading

Days After AbbVie-Shire Deal, Obama Slams Tax Inverters

AbbVie recently announced intentions to acquire Shire Pharmaceuticals, and shifting their HQ to Ireland. Obama had some strong words about the practice, known as “Tax Inversion.” When a company acquires another that has business in Ireland, it is possible for that company to shift their HQ from the United States to their newly acquired assets […]

Continue Reading

Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system

July 24, 2014: Royal Philips today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its innovative ultra mobile ultrasound system, VISIQ, in the U.S. VISIQ is the first Philips ultrasound system to combine the benefits of greater mobility, performance and simplicity into a single miniaturized solution, helping clinicians increase access to […]

Continue Reading

Top
Geolocation